about
Management of intracerebral hemorrhage--use of statinsStatin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of omanTherapeutic management in patients with renal failure who experience an acute coronary syndrome.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Rhabdomyolysis with simvastatin.Management of dyslipidemia in women in the post-hormone therapy era.The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.Statin precipitated lactic acidosis?Statin response and pharmacokinetics variants.Inflammation in renal atherosclerotic disease.The role of statin drugs in the management of the peripheral vascular patient.Policosanol as a new inhibitor candidate for vascular calcification in diabetic hyperlipidemic rats.Rhabdomyolysis a result of azithromycin and statins: an unrecognized interactionStatin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.Towards companion diagnostics for the management of statin therapy.Drug interactions with statins.Drug-drug interaction with statins.Drug-drug interactions that interfere with statin metabolism.Effect of the interaction between atorvastatin and selective serotonin reuptake inhibitors on the blood redox equilibrium.Plasmapheresis in a patient with rhabdomyolysis: a case report.Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.Statins and modulation of oxidative stress.The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen.Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects.Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations.Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
P2860
Q26752952-F002A898-7D29-4777-B45D-4A1B4A027254Q28654581-E3D7335D-40E4-446D-97AE-29CA746B434BQ33571353-CE2F45A4-8780-494C-A6BB-25FEED9BAD31Q34429685-9A62A65B-3F7F-4F1B-921C-B5FA9B408288Q34526546-923EFE0E-A48A-43E3-9091-B356D746DDA1Q34722828-1207743A-4876-43AA-92FF-974BAF0F60FBQ35242280-E831ADE5-B2A7-4345-8064-CCA75E00DB0BQ35587965-40157E1C-9709-491A-A147-DBFE90A3995CQ36192738-BEC6864A-702A-4F6A-AF2E-751FF87DA501Q37197098-50B1E5AD-9147-4670-B79D-3F16B928EA6FQ37214238-2C9F50D0-061B-4896-BBC9-B027456C0F0AQ37347202-4C651E38-0FCD-4745-862D-EF162517F6A6Q37397811-A8D2CDE2-1BBF-4F0D-9732-DCDEF2716FB7Q37855316-7C4A36B6-4764-4432-80B1-68085970E488Q38089842-F719E6C6-41EF-4D3F-982B-65AD73FA4788Q38155016-F95770F6-38A0-45A7-83D3-1BEDC38F442FQ38177333-193E14E5-7E9F-4B76-821F-FCEAD69B99D9Q38522299-A788DC77-BC9D-4441-9D17-00B09873A32EQ39157378-7D757EF9-4567-418F-9B3D-6B23EEDB973CQ42230722-AFC5F700-EE1E-43E2-BDF7-F5000B1945D0Q42426348-A51FB93E-0EE3-4E0F-BBBA-0956DF7FC26CQ43215640-6A2D4A45-9283-4BFA-9A71-974049005E2AQ44670041-1ED56C65-5694-400A-9346-9190924AFE54Q46577508-ED0B28B6-28B2-4CD6-8BE3-8D8772FC9CF4Q46686112-41F354EA-6B2D-4854-B5CE-9CC848C51D9BQ46770291-616EC40A-028E-4C05-93F9-E409829EEF0FQ47805916-EFE8D271-C630-44A0-B436-C3DB9AD6A9E7Q50931664-F50CF1C0-A46E-4141-A82A-C38DF46878F9
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Safety considerations for statins.
@ast
Safety considerations for statins.
@en
type
label
Safety considerations for statins.
@ast
Safety considerations for statins.
@en
prefLabel
Safety considerations for statins.
@ast
Safety considerations for statins.
@en
P2093
P1476
Safety considerations for statins.
@en
P2093
Alberto Corsini
Chiara Bolego
Roberta Baetta
Rodolfo Paoletti
Stefano Bellosta
P304
P356
10.1097/00041433-200212000-00007
P577
2002-12-01T00:00:00Z